1.25.19 | Sleep
SWHR Response to NHLBI Women’s Health Working Group
SWHR responded to the National Heart, Lung, and Blood Institute (NHLBI) Women’s Health Working Group (WHWG) request for information regarding […]
1.22.19 | Policy
SWHR Supports Women’s Health Research Day Resolution
SWHR released a letter of support sent to both Sen. Tammy Duckworth (D-IL) and Rep. Jan Schakowsky (D-IL-09) in acknowledgment […]
12.14.18 | Policy
SWHR Encourages Inclusion of Women’s Voices in Patient-Focused Drug Development
In comments to the Food and Drug Administration (FDA) on its Patient-Focused Drug Development (PFDD) Program, SWHR encouraged inclusion of the […]
10.5.18 | Policy
SWHR Expresses Concerns Regarding CMS Step Therapy Proposal
SWHR sent a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma expressing concerns regarding a recent […]
8.8.18 | Policy
SWHR Comments on FDA Guidance on Pregnant Women in Clinical Trials
SWHR submitted comments to the federal Food and Drug Administration (FDA) regarding FDA’s recently issued draft guidance on recommendations for the […]
8.8.18 | Policy
SWHR Letter on Prioritization of Diagnostic Reform
SWHR signed on to a coalition letter to Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), as well as to […]
5.31.18 | Policy
SWHR Recommends ICER Delay Report on Endometriosis Treatments
In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence […]
5.9.18 | Policy
SWHR Calls for Oversight on Clinical Laboratory Diagnostics
Together with a committee of stakeholder organizations, SWHR sent a letter to congressional committee leadership urging Congress to reform the […]
5.8.18 | Policy
SWHR Input on ICER Migraine Therapies Draft Report
SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) on ICER’s new draft report regarding the effectiveness […]
2.16.18 | Policy
SWHR Contributes to Patient-Focused Drug Development Workshop
SWHR issued comments to the federal Food and Drug Administration (FDA) regarding its recent workshop on methodological approaches for collecting […]
